Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations

Journal of Allergy and Clinical Immunology

Volumn 142, Issue 5, 2018, Pages 1665-1669

  Forbes, Lisa R ^a,b   Vogel, Tiphanie P ^a,b   Cooper, Megan A ^c   Castro Wagner, Johana ^d   Schussler, Edith ^e,q   Weinacht, Katja G ^f   Plant, Ashley S ^g   Su, Helen C ^h   Allenspach, Eric J ⁱ   Slatter, Mary ^j   Abinun, Mario ^j   Lilic, Desa ^j   Cunningham Rundles, Charlotte ^e   Eckstein, Olive ^k   Olbrich, Peter ^h,l   Guillerman, R Paul ^a   Patel, Niraj C ^m   Demirdag, Yesim Y ⁿ   Zerbe, Christa ^h   Freeman, Alexandra F ^h   Holland, Steven M ^h   Szabolcs, Paul ^o   Gennery, Andrew ^j   Torgerson, Troy R ⁱ   Milner, Joshua D ^h   Leiding, Jennifer W ^d,p   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k TEXAS CHILDREN S CANCER CENTER   (United States)

^l HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^m Levine Children s Hospital   (United States)

ⁿ New York Presbyterian Morgan Stanley Children's Hospital ^*  (United States)

^o UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^p JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^q WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; JAKINIBS; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RUXOLITINIB; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TOFACITINIB;

ARTHRITIS; ARTICLE; AUTOIMMUNE HEPATITIS; BRONCHIECTASIS; CHRONIC LUNG DISEASE; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOCRINE DISEASE; ENTEROPATHY; GAIN OF FUNCTION MUTATION; HERPES ZOSTER; HUMAN; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MULTIPLE ORGAN FAILURE; OXYGEN CONSUMPTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; TOTAL PARENTERAL NUTRITION; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; FEMALE; GENETICS; IMMUNE DEFICIENCY; MALE; MULTICENTER STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; FEMALE; GAIN OF FUNCTION MUTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; JANUS KINASES; MALE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; PYRROLES; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TREATMENT OUTCOME;

EID: 85052750599     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2018.07.020     Document Type: Article

References (9)

1. Toubiana, J., Okada, S., Hiller, J., Oleastro, M., Lagos Gomez, M., Aldave Becerra, J.C., et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127 (2016), 3154–3164.
2. Vargas-Hernandez, A., Mace, E.M., Zimmerman, O., Zerbe, C.S., Freeman, A.F., Rosenzweig, S., et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol 141 (2018), 2142–2155.e5.
3. Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Allen, H.L., De Franco, E., et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 46 (2014), 812–814.
4. Milner, J.D., Vogel, T.P., Forbes, L., Ma, C.A., Stray-Pedersen, A., Niemela, J.E., et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125 (2015), 591–599.
5. Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P.J., Rumi, E., et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120 (2014), 513–520.
6. Loh, M.L., Tasian, S.K., Rabin, K.R., Brown, P., Magoon, D., Reid, J.M., et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer 62 (2015), 1717–1724.
7. Weinacht, K.G., Charbonnier, L.M., Alroqi, F., Plant, A., Qiao, Q., Wu, H., et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol 139 (2017), 1629–1640.e2.
8. Higgins, E., Al Shehri, T., McAleer, M.A., Conlon, N., Feighery, C., Lilic, D., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135 (2015), 551–553.
9. Leiding, J.W., Okada, S., Hagin, D., Abinun, M., Shcherbina, A., Balashov, D.N., et al. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol 141 (2018), 704–717.e5.